{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Cancer-therapy", "Immunotherapy", "Oligonucleotide", "mRNA", "miRNA", "siRNA"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37402038", "DateCompleted": {"Year": "2024", "Month": "02", "Day": "20"}, "DateRevised": {"Year": "2024", "Month": "02", "Day": "20"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "07", "Day": "04"}], "Language": ["eng"], "ELocationID": ["10.1007/s12010-023-04597-5"], "Journal": {"ISSN": "1559-0291", "JournalIssue": {"Volume": "196", "Issue": "3", "PubDate": {"Year": "2024", "Month": "Mar"}}, "Title": "Applied biochemistry and biotechnology", "ISOAbbreviation": "Appl Biochem Biotechnol"}, "ArticleTitle": "Transitional Insight into the RNA-Based Oligonucleotides in Cancer Treatment.", "Pagination": {"StartPage": "1685", "EndPage": "1711", "MedlinePgn": "1685-1711"}, "Abstract": {"AbstractText": ["Conventional cancer therapies with chemodrugs suffer from various disadvantages, such as irreversible side effects on the skin, heart, liver, and nerves with even fatal consequences. RNA-based therapeutic is a novel technology which offers great potential as non-toxic, non-infectious, and well-tolerable platform. Herein, we introduce different RNA-based platforms with a special focus on siRNA, miRNA, and mRNA applications in cancer treatment in order to better understand the details of their therapeutic effects. Of note, the co-delivery of RNAs with other distinct RNA or drugs has provided safe, efficient, and novel treatment modalities for cancer treatment."], "CopyrightInformation": "\u00a9 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran."}, {"Identifier": [], "Affiliation": "Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Tabasi", "ForeName": "Hamed", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran."}], "LastName": "Mollazadeh", "ForeName": "Samaneh", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biomedicine Department, Aarhus University, Aarhus, Denmark."}], "LastName": "Fazeli", "ForeName": "Elham", "Initials": "E"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Abnus", "ForeName": "Khalil", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Taghdisi", "ForeName": "Seyed Mohammad", "Initials": "SM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. ramezanim@mums.ac.ir."}, {"Identifier": [], "Affiliation": "Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. ramezanim@mums.ac.ir."}], "LastName": "Ramezani", "ForeName": "Mohammad", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. alibolandim@mums.ac.ir."}, {"Identifier": [], "Affiliation": "Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. alibolandim@mums.ac.ir."}], "LastName": "Alibolandi", "ForeName": "Mona", "Initials": "M"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Appl Biochem Biotechnol", "NlmUniqueID": "8208561", "ISSNLinking": "0273-2289"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Oligonucleotides"}, {"RegistryNumber": "0", "NameOfSubstance": "MicroRNAs"}, {"RegistryNumber": "0", "NameOfSubstance": "RNA, Small Interfering"}, {"RegistryNumber": "0", "NameOfSubstance": "RNA, Double-Stranded"}], "MeshHeadingList": [{"QualifierName": ["genetics", "therapeutic use"], "DescriptorName": "Oligonucleotides"}, {"QualifierName": ["genetics", "therapeutic use"], "DescriptorName": "MicroRNAs"}, {"QualifierName": ["genetics", "therapeutic use"], "DescriptorName": "RNA, Small Interfering"}, {"QualifierName": [], "DescriptorName": "RNA, Double-Stranded"}, {"QualifierName": ["drug therapy", "genetics"], "DescriptorName": "Neoplasms"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global cancer statistics 2020: GLOBOCAN Estimates of Incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209\u2013249.", "ArticleIdList": ["33538338"]}, {"Citation": "Qiao, J., Liu, Z., & Fu, Y. X. (2016). Adapting conventional cancer treatment for immunotherapy. Journal of Molecular Medicine (Berlin, Germany), 94(5), 489\u2013495.", "ArticleIdList": ["26910191", "10.1007/s00109-016-1393-4"]}, {"Citation": "Qian, C. N., Mei, Y., & Zhang, J. (2017). Cancer metastasis: Issues and challenges. Chinese Journal of Cancer, 36(1), 38.", "ArticleIdList": ["28372569", "5379757", "10.1186/s40880-017-0206-7"]}, {"Citation": "Sadat, S. M. A., Wuest, M., Paiva, I. M., Munira, S., Sarrami, N., Sanaee, F., et al. (2021). Nano-delivery of a novel inhibitor of polynucleotide kinase/phosphatase (PNKP) for targeted sensitization of colorectal cancer to radiation-induced DNA damage. Frontiers in Oncology, 11, 772920.", "ArticleIdList": ["35004293", "8733593", "10.3389/fonc.2021.772920"]}, {"Citation": "Schirrmacher, V. (2019). From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review). International Journal of Oncology, 54(2), 407\u2013419.", "ArticleIdList": ["30570109", "10.3892/ijo.2018.4661"]}, {"Citation": "Haghiralsadat, F., Amoabediny, G., Naderinezhad, S., Forouzanfar, T., Helder, M. N., & Zandieh-Doulabi, B. (2018). Preparation of PEGylated cationic nanoliposome-siRNA complexes for cancer therapy. Artif Cells Nanomed Biotechnol., 46(sup1), 684\u2013692.", "ArticleIdList": ["29475393", "10.1080/21691401.2018.1434533"]}, {"Citation": "Guan, S., Yu, X., Li, J., Xu, H., Han, W., Shi, G., et al. (2019). Delivery of survivin siRNA using cationic diphenylalanine vesicles. Chemical Research in Chinese Universities., 35(3), 434\u2013439.", "ArticleIdList": ["10.1007/s40242-019-8184-8"]}, {"Citation": "Xiong, X. B., Uludag, H., & Lavasanifar, A. (2010). Virus-mimetic polymeric micelles for targeted siRNA delivery. Biomaterials, 31(22), 5886\u20135893.", "ArticleIdList": ["20427082", "10.1016/j.biomaterials.2010.03.075"]}, {"Citation": "Zheng, B., Chen, L., Pan, C. C., Wang, J. Z., Lu, G. R., Yang, S. X., et al. (2018). Targeted delivery of miRNA-204-5p by PEGylated polymer nanoparticles for colon cancer therapy. Nanomedicine, 13(7), 769\u2013785.", "ArticleIdList": ["29460671", "10.2217/nnm-2017-0345"]}, {"Citation": "Han, S., Li, G., Jia, M., Zhao, Y., He, C., Huang, M., et al. (2021). Delivery of anti-miRNA-221 for colorectal carcinoma therapy using modified cord blood mesenchymal stem cells-derived exosomes. Frontiers in Molecular Biosciences, 8, 743013.", "ArticleIdList": ["34616773", "8488275", "10.3389/fmolb.2021.743013"]}, {"Citation": "Yang, C., Yin, M., Xu, G., Lin, W. J., Chen, J., Zhang, Y., et al. (2019). Biodegradable polymers as a noncoding miRNA nanocarrier for multiple targeting therapy of human hepatocellular carcinoma. Adv Healthc Mater., 8(8), e1801318.", "ArticleIdList": ["30829008", "10.1002/adhm.201801318"]}, {"Citation": "Muller, K., Klein, P. M., Heissig, P., Roidl, A., & Wagner, E. (2016). EGF receptor targeted lipo-oligocation polyplexes for antitumoral siRNA and miRNA delivery. Nanotechnology, 27(46), 464001.", "ArticleIdList": ["27736810", "10.1088/0957-4484/27/46/464001"]}, {"Citation": "Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines - A new era in vaccinology. Nature Reviews Drug Discovery, 17(4), 261\u2013279.", "ArticleIdList": ["29326426", "5906799", "10.1038/nrd.2017.243"]}, {"Citation": "Wang, Y., Su, H. H., Yang, Y., Hu, Y., Zhang, L., Blancafort, P., et al. (2013). Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Molecular Therapy, 21(2), 358\u2013367.", "ArticleIdList": ["23229091", "10.1038/mt.2012.250"]}, {"Citation": "Henderson, J. M., Ujita, A., Hill, E., Yousif-Rosales, S., Smith, C., Ko, N., et al. (2021). Cap 1 messenger RNA synthesis with co-transcriptional CleanCap((R)) analog by in vitro transcription. Curr Protoc., 1(2), e39.", "ArticleIdList": ["33524237", "10.1002/cpz1.39"]}, {"Citation": "Pardi, N., Muramatsu, H., Weissman, D., & Kariko, K. (2013). In vitro transcription of long RNA containing modified nucleosides. Methods in Molecular Biology, 969, 29\u201342.", "ArticleIdList": ["23296925", "10.1007/978-1-62703-260-5_2"]}, {"Citation": "Rosigkeit, S., Meng, M., Grunwitz, C., Gomes, P., Kreft, A., Hayduk, N., et al. (2018). Monitoring translation activity of mRNA-loaded nanoparticles in mice. Molecular Pharmaceutics, 15(9), 3909\u20133919.", "ArticleIdList": ["30028629", "10.1021/acs.molpharmaceut.8b00370"]}, {"Citation": "Delcayre, A., Shu, H., & Le Pecq, J.-B. (2005). Dendritic cell-derived exosomes in cancer immunotherapy: Exploiting nature\u2019s antigen delivery pathway. Expert Review of Anticancer Therapy., 5(3), 537\u2013547.", "ArticleIdList": ["16001959", "10.1586/14737140.5.3.537"]}, {"Citation": "Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., & Thakur, A. (2020). Opportunities and challenges in the delivery of mRNA-based vaccines. Pharmaceutics., 12(2), 102.", "ArticleIdList": ["32013049", "7076378", "10.3390/pharmaceutics12020102"]}, {"Citation": "Tiera, M. J., Shi, Q., Barbosa, H. F. G., & Fernandes, J. C. (2013). Polymeric systems as nanodevices for siRNA delivery. Current Gene Therapy., 13(5), 358\u2013369.", "ArticleIdList": ["24369060", "10.2174/156652321305131212125042"]}, {"Citation": "Pushparaj, P. N., & Melendez, A. J. (2006). Short interfering RNA (siRNA) as a novel therapeutic. Clinical and Experimental Pharmacology and Physiology, 33(5\u20136), 504\u2013510.", "ArticleIdList": ["16700886", "10.1111/j.1440-1681.2006.04399.x"]}, {"Citation": "Satterlee, A. B., & Huang, L. (2014). Cancer therapy with RNAi delivered by non-viral membrane/core nanoparticles. In M. K. Brenner, & M. C. Hung (Eds.),\u00a0Cancer Gene Therapy by Viral and Non\u2010viral Vectors\u00a0(pp. 61\u201378).\u00a0Wiley"}, {"Citation": "Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., et al. (2010). Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature, 464(7291), 1067\u20131070.", "ArticleIdList": ["20305636", "2855406", "10.1038/nature08956"]}, {"Citation": "Cao, J. (2014). The functional role of long non-coding RNAs and epigenetics. Biological Procedures Online., 16(1), 42.", "ArticleIdList": ["10.1186/1480-9222-16-11"]}, {"Citation": "Kim, M., Jeong, M., Hur, S., Cho, Y., Park, J., & Jung, H., et al. (2021). Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver. Science Advances, 7(9), eabf4398."}, {"Citation": "Perche, F., Clemencon, R., Schulze, K., Ebensen, T., Guzman, C. A., & Pichon, C. (2019). Neutral lipopolyplexes for in vivo delivery of conventional and replicative RNA vaccine. Molecular Therapy-Nucleic Acids, 17, 767\u2013775.", "ArticleIdList": ["31446119", "6716064", "10.1016/j.omtn.2019.07.014"]}, {"Citation": "Yang, D. C., Eldredge, A. C., Hickey, J. C., Muradyan, H., & Guan, Z. B. (2020). Multivalent peptide-functionalized bioreducible polymers for cellular delivery of various RNAs. Biomacromolecules, 21(4), 1613\u20131624.", "ArticleIdList": ["32091881", "10.1021/acs.biomac.0c00211"]}, {"Citation": "Frohlich, T., & Wagner, E. (2010). Peptide- and polymer-based delivery of therapeutic RNA. Soft Matter, 6(2), 226\u2013234.", "ArticleIdList": ["10.1039/B916053A"]}, {"Citation": "Yu, T., Wang, H., Zhang, Y., Wang, X., & Han, B. (2020). The delivery of RNA-interference therapies based on engineered hydrogels for bone tissue regeneration. Frontiers in Bioengineering and Biotechnology, 8, 445."}, {"Citation": "Zhou, Y., Zhou, G. Y., Tian, C. F., Jiang, W. E., Jin, L., Zhang, C. Y., et al. (2016). Exosome-mediated small RNA delivery for gene therapy. Wiley Interdisciplinary Reviews-RNA, 7(6), 758\u2013771.", "ArticleIdList": ["27196002", "10.1002/wrna.1363"]}, {"Citation": "Xue, V. W., Wong, S. C. C., Song, G. Q., & Cho, W. C. S. (2020). Promising RNA-based cancer gene therapy using extracellular vesicles for drug delivery. Expert Opinion on Biological Therapy, 20(7), 767\u2013777.", "ArticleIdList": ["32125904", "10.1080/14712598.2020.1738377"]}, {"Citation": "Mahmoodi Chalbatani, G., Dana, H., Gharagouzloo, E., Grijalvo, S., Eritja, R., Logsdon, C. D., et al. (2019). Small interfering RNAs (siRNAs) in cancer therapy: A nano-based approach. International Journal of Nanomedicine, 14, 3111\u20133128.", "ArticleIdList": ["31118626", "6504672", "10.2147/IJN.S200253"]}, {"Citation": "Bernstein, E., Caudy, A. A., Hammond, S. M., & Hannon, G. J. (2001). Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature, 409(6818), 363\u2013366.", "ArticleIdList": ["11201747", "10.1038/35053110"]}, {"Citation": "Crooke, S. T., Wang, S., Vickers, T. A., Shen, W., & Liang, X. H. (2017). Cellular uptake and trafficking of antisense oligonucleotides. Nature Biotechnology, 35(3), 230\u2013237.", "ArticleIdList": ["28244996", "10.1038/nbt.3779"]}, {"Citation": "Tatiparti, K., Sau, S., Kashaw, S. K., & Iyer, A. K. (2017). siRNA delivery strategies: A comprehensive review of recent developments. Nanomaterials (Basel)s, 7(4), 77.", "ArticleIdList": ["10.3390/nano7040077"]}, {"Citation": "Mahmoodi Chalbatani, G., Dana, H., Gharagouzloo, E., Grijalvo, S., Eritja, R., Logsdon, C. D., et al. (2019). Small interfering RNAs (siRNAs) in cancer therapy: A nano-based approach. International Journal of Nanomedicine, 14, 3111\u20133128.", "ArticleIdList": ["31118626", "6504672", "10.2147/IJN.S200253"]}, {"Citation": "Xu, C.-F., & Wang, J. (2015). Delivery systems for siRNA drug development in cancer therapy. Asian Journal of Pharmaceutical Sciences, 10(1), 1\u201312.", "ArticleIdList": ["10.1016/j.ajps.2014.08.011"]}, {"Citation": "Behlke, M. A. (2008). Chemical modification of siRNAs for in vivo use. Oligonucleotides, 18(4), 305\u2013319.", "ArticleIdList": ["19025401", "10.1089/oli.2008.0164"]}, {"Citation": "\u015eenel, B., & \u00d6zt\u00fcrk, A. A. (2019). New approaches to tumor therapy with siRNA-decorated and chitosan-modified PLGA nanoparticles. Drug Development and Industrial Pharmacy., 45(11), 1835\u20131848.", "ArticleIdList": ["31491363", "10.1080/03639045.2019.1665061"]}, {"Citation": "Kumar Tekade, R., Maheshwari, R., Sharma, P., Tekade, M., & Singh Chauhan, A. (2015). siRNA therapy, challenges and underlying perspectives of dendrimer as delivery vector. Current Pharmaceutical Design., 21(31), 4614\u201336.", "ArticleIdList": ["10.2174/138161282131151013192116"]}, {"Citation": "Subhan, M. A., Attia, S. A., & Torchilin, V. P. (2021). Advances in siRNA delivery strategies for the treatment of MDR cancer. Life Sciences, 274, 119337.", "ArticleIdList": ["33713664", "10.1016/j.lfs.2021.119337"]}, {"Citation": "Yuan, X., Naguib, S., & Wu, Z. (2011). Recent advances of siRNA delivery by nanoparticles. Expert Opinion on Drug Delivery., 8(4), 521\u2013536.", "ArticleIdList": ["21413903", "10.1517/17425247.2011.559223"]}, {"Citation": "Yoo, B., & Medarova, Z. (2017). Nanoformulations for pharmacological siRNA delivery in cancer. In J. W. M. Bulte & M. M. J. Modo (Eds.), Design and applications of nanoparticles in biomedical imaging (pp. 171\u2013186). Springer International Publishing.", "ArticleIdList": ["10.1007/978-3-319-42169-8_8"]}, {"Citation": "Feng, Q., & Xiao, K. (2022). Nanoparticle-mediated delivery of STAT3 inhibitors in the treatment of lung cancer. Pharmaceutics, 14(12), 2787.", "ArticleIdList": ["36559280", "9781630", "10.3390/pharmaceutics14122787"]}, {"Citation": "Li, Z., Chen, G., Ding, L., Wang, Y., Zhu, C., Wang, K., et al. (2019). Increased survival by pulmonary treatment of established lung metastases with dual STAT3/CXCR4 inhibition by siRNA nanoemulsions. Molecular Therapy, 27(12), 2100\u20132110.", "ArticleIdList": ["31481310", "6904825", "10.1016/j.ymthe.2019.08.008"]}, {"Citation": "Wang, J., Liu, S. Y., Chang, Y., Fang, L., Han, K., & Li, M. (2018). High efficient delivery of siRNA into tumor cells by positively charged carbon dots. Journal of Macromolecular Science Part a-Pure and Applied Chemistry, 55(11\u201312), 770\u2013774.", "ArticleIdList": ["10.1080/10601325.2018.1526043"]}, {"Citation": "Jose, A., Labala, S., Ninave, K. M., Gade, S. K., & Venuganti, V. V. K. (2018). Effective skin cancer treatment by topical co-delivery of curcumin and STAT3 siRNA using cationic liposomes. An Official Journal of the American Association of Pharmaceutical Scientists, 19(1), 166\u2013175."}, {"Citation": "Su, W. P., Cheng, F. Y., Shieh, D. B., Yeh, C. S., & Su, W. C. (2012). PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells. International Journal of Nanomedicine, 7, 4269\u20134283.", "ArticleIdList": ["22904633", "3418083", "10.2147/IJN.S33666"]}, {"Citation": "Masjedi, A., Ahmadi, A., Atyabi, F., Farhadi, S., Irandoust, M., Khazaei-Poul, Y., et al. (2020). Silencing of IL-6 and STAT3 by siRNA loaded hyaluronate-N, N, N-trimethyl chitosan nanoparticles potently reduces cancer cell progression. International Journal of Biological Macromolecules, 149, 487\u2013500.", "ArticleIdList": ["32004600", "10.1016/j.ijbiomac.2020.01.273"]}, {"Citation": "Joshi, N., Hajizadeh, F., Ansari Dezfouli, E., Zekiy, A. O., Nabi Afjadi, M., Mousavi, S. M., et al. (2021). Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression. Life Sciences, 275, 119369.", "ArticleIdList": ["33745894", "10.1016/j.lfs.2021.119369"]}, {"Citation": "Alshamsan, A., Hamdy, S., Samuel, J., El-Kadi, A. O. S., Lavasanifar, A., & Uluda\u011f, H. (2010). The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine. Biomaterials, 31(6), 1420\u20131428.", "ArticleIdList": ["19913908", "10.1016/j.biomaterials.2009.11.003"]}, {"Citation": "Zhang, H., Men, K., Pan, C., Gao, Y., Li, J., Lei, S., et al. (2020). Treatment of colon cancer by degradable rrPPC nano-conjugates delivered STAT3 siRNA. International Journal of Nanomedicine, 15, 9875\u20139890.", "ArticleIdList": ["33324056", "7732178", "10.2147/IJN.S277845"]}, {"Citation": "Labala, S., Jose, A., Chawla, S. R., Khan, M. S., Bhatnagar, S., Kulkarni, O. P., et al. (2017). Effective melanoma cancer suppression by iontophoretic co-delivery of STAT3 siRNA and imatinib using gold nanoparticles. International Journal of Pharmaceutics, 525(2), 407\u2013417.", "ArticleIdList": ["28373100", "10.1016/j.ijpharm.2017.03.087"]}, {"Citation": "Shakeran, Z., Varshosaz, J., Keyhanfar, M., Mohammad-Beigi, H., Rahimi, K., & Sutherland, D. S. (2022). Co-delivery of STAT3 siRNA and methotrexate in breast cancer cells. Artificial Cells, Nanomedicine, and Biotechnology., 50(1), 29\u201339.", "ArticleIdList": ["35132929", "10.1080/21691401.2022.2030746"]}, {"Citation": "Ngamcherdtrakul, W., Morry, J., Gu, S., Castro, D. J., Goodyear, S. M., Sangvanich, T., et al. (2015). Cationic polymer modified mesoporous silica nanoparticles for targeted siRNA delivery to HER2+ breast cancer. Advanced Functional Materials., 25(18), 2646\u20132659.", "ArticleIdList": ["26097445", "4469082", "10.1002/adfm.201404629"]}, {"Citation": "Bae, K. H., Lee, K., Kim, C., & Park, T. G. (2011). Surface functionalized hollow manganese oxide nanoparticles for cancer targeted siRNA delivery and magnetic resonance imaging. Biomaterials, 32(1), 176\u2013184.", "ArticleIdList": ["20934746", "10.1016/j.biomaterials.2010.09.039"]}, {"Citation": "Liang, S.-F., Zuo, F.-F., Yin, B.-C., & Ye, B.-C. (2022). Delivery of siRNA based on engineered exosomes for glioblastoma therapy by targeting STAT3. Biomaterials Science., 10(6), 1582\u20131590.", "ArticleIdList": ["35179533", "10.1039/D1BM01723C"]}, {"Citation": "Tang, M., Chen, Y., Li, B., Sugimoto, H., Yang, S., Yang, C., et al. (2021). Therapeutic targeting of STAT3 with small interference RNAs and antisense oligonucleotides embedded exosomes in liver fibrosis. The FASEB Journal, 35(5), e21557.", "ArticleIdList": ["33855751", "10.1096/fj.202002777RR"]}, {"Citation": "Posocco, P., Liu, X. X., Laurini, E., Marson, D., Chen, C., Liu, C., et al. (2013). Impact of siRNA overhangs for dendrimer-mediated siRNA delivery and gene silencing. Molecular Pharmaceutics., 10(8), 3262\u20133273.", "ArticleIdList": ["23841848", "10.1021/mp400329g"]}, {"Citation": "Lim, M. S. H., Nishiyama, Y., Ohtsuki, T., Watanabe, K., Kobuchi, H., Kobayashi, K., et al. (2021). Lactosome-conjugated siRNA nanoparticles for photo-enhanced gene silencing in cancer cells. Journal of Pharmaceutical Sciences, 110(4), 1788\u20131798.", "ArticleIdList": ["33529684", "10.1016/j.xphs.2021.01.026"]}, {"Citation": "Ben-David-Naim, M., Dagan, A., Grad, E., Aizik, G., Nordling-David, M. M., Morss Clyne, A., et al. (2019). Targeted siRNA nanoparticles for mammary carcinoma therapy. Cancers (Basel), 11(4), 442.", "ArticleIdList": ["30934857", "10.3390/cancers11040442"]}, {"Citation": "Zorn, E., Nelson, E. A., Mohseni, M., Porcheray, F., Kim, H., Litsa, D., et al. (2006). IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood, 108(5), 1571\u20131579.", "ArticleIdList": ["16645171", "1895505", "10.1182/blood-2006-02-004747"]}, {"Citation": "Yu, H., Pardoll, D., & Jove, R. (2009). STATs in cancer inflammation and immunity: A leading role for STAT3. Nature Reviews Cancer, 9(11), 798\u2013809.", "ArticleIdList": ["19851315", "4856025", "10.1038/nrc2734"]}, {"Citation": "Harris, T. J., Grosso, J. F., Yen, H.-R., Xin, H., Kortylewski, M., Albesiano, E., et al. (2007). Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. The Journal of Immunology, 179(7), 4313\u20134317.", "ArticleIdList": ["17878325", "10.4049/jimmunol.179.7.4313"]}, {"Citation": "Yu, H., & Jove, R. (2004). The STATs of cancer \u2014 New molecular targets come of age. Nature Reviews Cancer, 4(2), 97\u2013105.", "ArticleIdList": ["14964307", "10.1038/nrc1275"]}, {"Citation": "Yu, H., Kortylewski, M., & Pardoll, D. (2007). Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nature Reviews Immunology, 7(1), 41\u201351.", "ArticleIdList": ["17186030", "10.1038/nri1995"]}, {"Citation": "Jing, N., & Tweardy, D. J. (2005). Targeting Stat3 in cancer therapy. Anti-Cancer Drugs, 16(6), 601\u2013607."}, {"Citation": "Zhang, H., Men, K., Pan, C., Gao, Y., Li, J., Lei, S., et al. (2020). Treatment of colon cancer by degradable rrPPC nano-conjugates delivered STAT3 siRNA. International Journal of Nanomedicine, 15, 9875\u20139890.", "ArticleIdList": ["33324056", "7732178", "10.2147/IJN.S277845"]}, {"Citation": "Das, J., Das, S., Paul, A., Samadder, A., Bhattacharyya, S. S., & Khuda-Bukhsh, A. R. (2014). Assessment of drug delivery and anticancer potentials of nanoparticles-loaded siRNA targeting STAT3 in lung cancer, in vitro and in vivo. Toxicology Letters, 225(3), 454\u2013466.", "ArticleIdList": ["24440344", "10.1016/j.toxlet.2014.01.009"]}, {"Citation": "Zhang, S., Zhang, X., Lei, W., Liang, J., Xu, Y., Liu, H., et al. (2019). Genome-wide profiling reveals alternative polyadenylation of mRNA in human non-small cell lung cancer. Journal of Translational Medicine, 17(1), 257.", "ArticleIdList": ["31391087", "6686416", "10.1186/s12967-019-1986-0"]}, {"Citation": "Yhee, J. Y., Song, S., Lee, S. J., Park, S. G., Kim, K. S., Kim, M. G., et al. (2015). Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance. Journal of Controlled Release, 198, 1\u20139.", "ArticleIdList": ["25481438", "10.1016/j.jconrel.2014.11.019"]}, {"Citation": "Saad, M., Garbuzenko, O. B., & Minko, T. (2008). Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (London, England), 3(6), 761\u2013776.", "ArticleIdList": ["19025451", "10.2217/17435889.3.6.761"]}, {"Citation": "Falamarzian, A., Aliabadi, H. M., Molavi, O., Seubert, J. M., Lai, R., Uludag, H., et al. (2014). Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy. Journal of Biomedical Materials Research. Part A, 102(9), 3216\u20133228.", "ArticleIdList": ["24167124", "10.1002/jbm.a.34992"]}, {"Citation": "Dorraki, N., Ghale-Noie, Z. N., Ahmadi, N. S., Keyvani, V., Bahadori, R. A., Nejad, A. S., et al. (2021). miRNA-148b and its role in various cancers. Epigenomics, 13(24), 1939\u20131960.", "ArticleIdList": ["34852637", "10.2217/epi-2021-0155"]}, {"Citation": "Mollazadeh, S., Fazly Bazzaz, B. S., Neshati, V., de Vries, A. A. F., Naderi-Meshkin, H., Mojarad, M., et al. (2019). Overexpression of MicroRNA-148b-3p stimulates osteogenesis of human bone marrow-derived mesenchymal stem cells: The role of MicroRNA-148b-3p in osteogenesis. BMC Medical Genetics, 20(1), 117.", "ArticleIdList": ["31262253", "6604430", "10.1186/s12881-019-0854-3"]}, {"Citation": "Devi, G. R. (2006). siRNA-based approaches in cancer therapy. Cancer Gene Therapy, 13(9), 819\u2013829.", "ArticleIdList": ["16424918", "10.1038/sj.cgt.7700931"]}, {"Citation": "Si, W., Shen, J., Zheng, H., & Fan, W. (2019). The role and mechanisms of action of microRNAs in cancer drug resistance. Clinical Epigenetics, 11(1), 25.", "ArticleIdList": ["30744689", "6371621", "10.1186/s13148-018-0587-8"]}, {"Citation": "Bonneau, E., Neveu, B., Kostantin, E., Tsongalis, G. J., & De Guire, V. (2019). How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market. Ejifcc, 30(2), 114\u2013127.", "ArticleIdList": ["31263388", "6599191"]}, {"Citation": "Huang, T., Kang, W., Zhang, B., Wu, F., Dong, Y., Tong, J. H., et al. (2016). miR-508-3p concordantly silences NFKB1 and RELA to inactivate canonical NF-kappaB signaling in gastric carcinogenesis. Molecular Cancer, 15, 9.", "ArticleIdList": ["26801246", "4724081", "10.1186/s12943-016-0493-7"]}, {"Citation": "Gao, S., Tian, H., Guo, Y., Li, Y., Guo, Z., Zhu, X., et al. (2015). miRNA oligonucleotide and sponge for miRNA-21 inhibition mediated by PEI-PLL in breast cancer therapy. Acta Biomaterialia, 25, 184\u2013193.", "ArticleIdList": ["26169933", "10.1016/j.actbio.2015.07.020"]}, {"Citation": "Eckburg, A., Dein, J., Berei, J., Schrank, Z., & Puri, N. (2020). Oligonucleotides and microRNAs targeting telomerase subunits in cancer therapy. Cancers (Basel), 12(9), 2337.", "ArticleIdList": ["32825005", "10.3390/cancers12092337"]}, {"Citation": "Komatsu, S., Kitai, H., & Suzuki, H. I. (2023). Network regulation of microRNA biogenesis and target interaction. CELLS, 12(2), 306.", "ArticleIdList": ["36672241", "9856966", "10.3390/cells12020306"]}, {"Citation": "Merritt, W. M., Lin, Y. G., Han, L. Y., Kamat, A. A., Spannuth, W. A., Schmandt, R., et al. (2008). Dicer, Drosha, and outcomes in patients with ovarian cancer. New England Journal of Medicine, 359(25), 2641\u20132650.", "ArticleIdList": ["19092150", "10.1056/NEJMoa0803785"]}, {"Citation": "Gaur, A. B., Holbeck, S. L., Colburn, N. H., & Israel, M. A. (2011). Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo. Neuro-Oncology, 13(6), 580\u2013590.", "ArticleIdList": ["21636706", "3107097", "10.1093/neuonc/nor033"]}, {"Citation": "Zhang, Y., Buhrman, J. S., Liu, Y., Rayahin, J. E., & Gemeinhart, R. A. (2016). Reducible micelleplexes are stable systems for anti-miRNA delivery in cerebrospinal fluid. Molecular Pharmaceutics, 13(6), 1791\u20131799.", "ArticleIdList": ["27177352", "6961805", "10.1021/acs.molpharmaceut.5b00933"]}, {"Citation": "Zhang, Y., Kollmer, M., Buhrman, J. S., Tang, M. Y., & Gemeinhart, R. A. (2014). Arginine-rich, cell penetrating peptide-anti-microRNA complexes decrease glioblastoma migration potential. Peptides, 58, 83\u201390.", "ArticleIdList": ["24969623", "4129943", "10.1016/j.peptides.2014.06.008"]}, {"Citation": "Hatakeyama, H., Murata, M., Sato, Y., Takahashi, M., Minakawa, N., Matsuda, A., et al. (2014). The systemic administration of an anti-miRNA oligonucleotide encapsulated pH-sensitive liposome results in reduced level of hepatic microRNA-122 in mice. Journal of Controlled Release, 173, 43\u201350.", "ArticleIdList": ["24511611", "10.1016/j.jconrel.2013.10.023"]}, {"Citation": "Avci-Adali, M., & Santos, H. A. (2022). Current trends in delivery of non-viral nucleic acid-based therapeutics for improved efficacy. Advanced Drug Delivery Reviews, 185, 114297.", "ArticleIdList": ["35427721", "9005216", "10.1016/j.addr.2022.114297"]}, {"Citation": "Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., et al. (2015). Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. Journal of Controlled Release, 217, 345\u2013351.", "ArticleIdList": ["26264835", "4624045", "10.1016/j.jconrel.2015.08.007"]}, {"Citation": "Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021). Lipid nanoparticles for mRNA delivery. Nature Reviews Materials, 6(12), 1078\u20131094.", "ArticleIdList": ["34394960", "8353930", "10.1038/s41578-021-00358-0"]}, {"Citation": "Han, H., Bartolo, R., Li, J., Shahbazi, M. A., & Santos, H. A. (2022). Biomimetic platelet membrane-coated nanoparticles for targeted therapy. European Journal of Pharmaceutics and Biopharmaceutics, 172, 1\u201315.", "ArticleIdList": ["35074554", "10.1016/j.ejpb.2022.01.004"]}, {"Citation": "Najibi, A. J., Dellacherie, M. O., Shih, T. Y., Doherty, E. J., White, D. A., Bauleth-Ramos, T., et al. (2022). Scaffold vaccines for generating robust and tunable antibody responses. Advanced Functional Materials, 32(16), 2110905.", "ArticleIdList": ["10.1002/adfm.202110905"]}, {"Citation": "Li, J., Huang, D., Cheng, R., Figueiredo, P., Fontana, F., Correia, A., et al. (2022). Multifunctional biomimetic nanovaccines based on photothermal and weak-immunostimulatory nanoparticulate cores for the immunotherapy of solid tumors. Advanced Materials, 34(9), e2108012.", "ArticleIdList": ["34877724", "10.1002/adma.202108012"]}, {"Citation": "Melamed, J. R., Hajj, K. A., Chaudhary, N., Strelkova, D., Arral, M. L., Pardi, N., et al. (2022). Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery. Journal of Controlled Release, 341, 206\u2013214.", "ArticleIdList": ["34801660", "10.1016/j.jconrel.2021.11.022"]}, {"Citation": "Mu, Z., Wiehe, K., Saunders, K. O., Henderson, R., Cain, D. W., Parks, R., et al. (2022). mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. Cell Reports, 38(11), 110514.", "ArticleIdList": ["35294883", "10.1016/j.celrep.2022.110514"]}, {"Citation": "Kantarjian, H., Stein, A., Gokbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J. M., et al. (2017). Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. New England Journal of Medicine, 376(9), 836\u2013847.", "ArticleIdList": ["28249141", "10.1056/NEJMoa1609783"]}, {"Citation": "Sahin, U., Kariko, K., & Tureci, O. (2014). mRNA-based therapeutics\u2013Developing a new class of drugs. Nature Reviews. Drug Discovery, 13(10), 759\u2013780.", "ArticleIdList": ["25233993", "10.1038/nrd4278"]}, {"Citation": "Mallory, K. L., Taylor, J. A., Zou, X., Waghela, I. N., Schneider, C. G., Sibilo, M. Q., et al. (2021). Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice. NPJ Vaccines, 6(1), 84.", "ArticleIdList": ["34145286", "8213722", "10.1038/s41541-021-00345-0"]}, {"Citation": "Stadler, C. R., Bahr-Mahmud, H., Celik, L., Hebich, B., Roth, A. S., Roth, R. P., et al. (2017). Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nature Medicine, 23(7), 815\u2013817.", "ArticleIdList": ["28604701", "10.1038/nm.4356"]}, {"Citation": "Lei, S., Zhang, X., Men, K., Gao, Y., Yang, X., Wu, S., et al. (2020). Efficient colorectal cancer gene therapy with IL-15 mRNA nanoformulation. Molecular Pharmaceutics, 17(9), 3378\u20133391.", "ArticleIdList": ["32787272", "10.1021/acs.molpharmaceut.0c00451"]}, {"Citation": "Forterre, A. V., Wang, J. H., Delcayre, A., Kim, K., Green, C., Pegram, M. D., et al. (2020). Extracellular vesicle-mediated in vitro transcribed mRNA delivery for treatment of HER2(+) breast cancer xenografts in mice by prodrug CB1954 without general toxicity. Molecular Cancer Therapeutics, 19(3), 858\u2013867.", "ArticleIdList": ["31941722", "7056535", "10.1158/1535-7163.MCT-19-0928"]}, {"Citation": "Miao, L., Zhang, Y., & Huang, L. (2021). mRNA vaccine for cancer immunotherapy. Molecular Cancer, 20(1), 41.", "ArticleIdList": ["33632261", "7905014", "10.1186/s12943-021-01335-5"]}, {"Citation": "Mockey, M., Bourseau, E., Chandrashekhar, V., Chaudhuri, A., Lafosse, S., Le Cam, E., et al. (2007). mRNA-based cancer vaccine: Prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes. Cancer Gene Therapy, 14(9), 802\u2013814.", "ArticleIdList": ["17589432", "10.1038/sj.cgt.7701072"]}, {"Citation": "Le Moignic, A., Malard, V., Benvegnu, T., Lemiegre, L., Berchel, M., Jaffres, P. A., et al. (2018). Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells. Journal of Controlled Release, 278, 110\u2013121.", "ArticleIdList": ["29630987", "10.1016/j.jconrel.2018.03.035"]}, {"Citation": "Salomon, N., Vascotto, F., Selmi, A., Vormehr, M., Quinkhardt, J., Bukur, T., et al. (2020). A liposomal RNA vaccine inducing neoantigen-specific CD4(+) T cells augments the antitumor activity of local radiotherapy in mice. Oncoimmunology, 9(1), 1771925.", "ArticleIdList": ["32923128", "7458669", "10.1080/2162402X.2020.1771925"]}, {"Citation": "Yan, J., Chen, R., Zhang, H., & Bryers, J. D. (2019). Injectable biodegradable chitosan-alginate 3D porous gel scaffold for mRNA vaccine delivery. Macromolecular Bioscience, 19(2), e1800242.", "ArticleIdList": ["30444317", "10.1002/mabi.201800242"]}, {"Citation": "Zhang, W., Liu, Y., Min Chin, J., & Phua, K. K. L. (2021). Sustained release of PKR inhibitor C16 from mesoporous silica nanoparticles significantly enhances mRNA translation and anti-tumor vaccination. European Journal of Pharmaceutics and Biopharmaceutics, 163, 179\u2013187.", "ArticleIdList": ["33771622", "10.1016/j.ejpb.2021.03.011"]}, {"Citation": "Coolen, A. L., Lacroix, C., Mercier-Gouy, P., Delaune, E., Monge, C., Exposito, J. Y., et al. (2019). Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation. Biomaterials, 195, 23\u201337.", "ArticleIdList": ["30610991", "10.1016/j.biomaterials.2018.12.019"]}, {"Citation": "Haabeth, O. A. W., Blake, T. R., McKinlay, C. J., Waymouth, R. M., Wender, P. A., & Levy, R. (2018). mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice. Proc Natl Acad Sci U S A, 115(39), E9153\u2013E9161.", "ArticleIdList": ["30201728", "6166849", "10.1073/pnas.1810002115"]}, {"Citation": "Meyer, R. A., Hussmann, G. P., Peterson, N. C., Santos, J. L., & Tuesca, A. D. (2022). A scalable and robust cationic lipid/polymer hybrid nanoparticle platform for mRNA delivery. International Journal of Pharmaceutics, 611, 121314.", "ArticleIdList": ["34838950", "10.1016/j.ijpharm.2021.121314"]}, {"Citation": "Alameh, M.-G., & Weissman, D. (2022). Chapter 7 - Nucleoside modifications of in vitro transcribed mRNA to reduce immunogenicity and improve translation of prophylactic and therapeutic antigens. In P. H. Giangrande, V. de Franciscis, & J. J. Rossi (Eds.), RNA Therapeutics (pp. 141\u201369). Academic Press.", "ArticleIdList": ["10.1016/B978-0-12-821595-1.00014-2"]}, {"Citation": "Knudson, C. J., Alves-Peixoto, P., Muramatsu, H., Stotesbury, C., Tang, L., Lin, P. J. C., et al. (2021). Lipid-nanoparticle-encapsulated mRNA vaccines induce protective memory CD8 T\u00a0cells against a lethal viral infection. Molecular Therapy., 29(9), 2769\u20132781.", "ArticleIdList": ["33992803", "8417516", "10.1016/j.ymthe.2021.05.011"]}, {"Citation": "Zuazo, M., Arasanz, H., Fernandez-Hinojal, G., Garcia-Granda, M. J., Gato, M., Bocanegra, A., et al. (2019). Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy. EMBO Molecular Medicine, 11(7), e10293.", "ArticleIdList": ["31273938", "6609910", "10.15252/emmm.201910293"]}, {"Citation": "De Ridder, K., Locy, H., Piccioni, E., Zuazo, M. I., Awad, R. M., & Verhulst, S., et al. (2022). TNF-\u03b1-secreting lung tumor-infiltrated monocytes play a pivotal role during anti-PD-L1 immunotherapy. Frontiers in Immunology, 13, 811867."}, {"Citation": "Tomb\u00e1cz, I., Weissman, D., & Pardi, N. (2021). Vaccination with messenger RNA: A promising alternative to DNA vaccination. In \u00c2. Sousa (Ed.), DNA Vaccines: Methods and Protocols (pp. 13\u201331). New York: Springer US.", "ArticleIdList": ["10.1007/978-1-0716-0872-2_2"]}, {"Citation": "Oberli, M. A., Reichmuth, A. M., Dorkin, J. R., Mitchell, M. J., Fenton, O. S., Jaklenec, A., et al. (2017). Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Letters, 17(3), 1326\u20131335.", "ArticleIdList": ["28273716", "10.1021/acs.nanolett.6b03329"]}, {"Citation": "Tombacz, I., Laczko, D., Shahnawaz, H., Muramatsu, H., Natesan, A., Yadegari, A., et al. (2021). Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs. Molecular Therapy, 29(11), 3293\u20133304.", "ArticleIdList": ["34091054", "8571164", "10.1016/j.ymthe.2021.06.004"]}, {"Citation": "Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., et al. (2016). Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature, 534(7607), 396\u2013401.", "ArticleIdList": ["27281205", "10.1038/nature18300"]}, {"Citation": "Fromm, P. D., Papadimitrious, M. S., Hsu, J. L., Van Kooten, L. N., Verma, N. D., Lo, T. H., et al. (2016). CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses. Oncoimmunology., 5(6), e1168555.", "ArticleIdList": ["27471645", "4938320", "10.1080/2162402X.2016.1168555"]}, {"Citation": "Persano, S., Guevara, M. L., Li, Z., Mai, J., Ferrari, M., Pompa, P. P., et al. (2017). Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. Biomaterials, 125, 81\u201389.", "ArticleIdList": ["28231510", "5378555", "10.1016/j.biomaterials.2017.02.019"]}, {"Citation": "Liu, L., Wang, Y., Miao, L., Liu, Q., Musetti, S., Li, J., et al. (2018). Combination immunotherapy of MUC1 mRNA nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer. Molecular Therapy, 26(1), 45\u201355.", "ArticleIdList": ["29258739", "10.1016/j.ymthe.2017.10.020"]}, {"Citation": "Hou, K. K., Pan, H., Ratner, L., Schlesinger, P. H., & Wickline, S. A. (2013). Mechanisms of nanoparticle-mediated siRNA transfection by melittin-derived peptides. ACS Nano, 7(10), 8605\u20138615.", "ArticleIdList": ["24053333", "4013830", "10.1021/nn403311c"]}, {"Citation": "Cavalli, R., Primo, L., Sessa, R., Chiaverina, G., di Blasio, L., Alongi, J., et al. (2017). The AGMA1 polyamidoamine mediates the efficient delivery of siRNA. Journal of Drug Targeting, 25(9\u201310), 891\u2013898.", "ArticleIdList": ["28817973", "10.1080/1061186X.2017.1363215"]}, {"Citation": "Xie, X., Yang, Y., Lin, W., Liu, H., Liu, H., Yang, Y., et al. (2015). Cell-penetrating peptide-siRNA conjugate loaded YSA-modified nanobubbles for ultrasound triggered siRNA delivery. Colloids and Surfaces. B, Biointerfaces, 136, 641\u2013650.", "ArticleIdList": ["26492155", "10.1016/j.colsurfb.2015.10.004"]}, {"Citation": "Ma, D., Tian, S., Baryza, J., Luft, J. C., & DeSimone, J. M. (2015). Reductively responsive hydrogel nanoparticles with uniform size, shape, and tunable composition for systemic siRNA delivery in vivo. Molecular Pharmaceutics, 12(10), 3518\u20133526.", "ArticleIdList": ["26287725", "4839470", "10.1021/acs.molpharmaceut.5b00054"]}, {"Citation": "Majidi Zolbanin, N., Jafari, R., Majidi, J., Atyabi, F., Yousefi, M., Jadidi-Niaragh, F., et al. (2018). Targeted co-delivery of docetaxel and cMET siRNA for treatment of mucin1 overexpressing breast cancer cells. Advanced Drug Delivery Reviews, 8(3), 383\u2013393."}, {"Citation": "Amri, J., Molaee, N., Karami, H., & Baazm, M. (2021). Combination of two miRNAs has a stronger effect on stimulating apoptosis, inhibiting cell growth, and increasing erlotinib sensitivity relative to single miRNA in A549 lung cancer cells. Biotechnology and Applied Biochemistry, 69, 1383\u20131394.", "ArticleIdList": ["34081797", "10.1002/bab.2211"]}, {"Citation": "Mittal, A., Chitkara, D., Behrman, S. W., & Mahato, R. I. (2014). Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. Biomaterials, 35(25), 7077\u20137087.", "ArticleIdList": ["24836307", "10.1016/j.biomaterials.2014.04.053"]}, {"Citation": "Zeng, W., Su, M., Anderson, K. S., & Sasada, T. (2014). Artificial antigen-presenting cells expressing CD80, CD70, and 4\u20131BB ligand efficiently expand functional T cells specific to tumor-associated antigens. Immunobiology, 219(8), 583\u2013592.", "ArticleIdList": ["24713579", "10.1016/j.imbio.2014.03.003"]}, {"Citation": "Liao, D., Luo, Y., Markowitz, D., Xiang, R., & Reisfeld, R. A. (2009). Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS ONE, 4(11), e7965.", "ArticleIdList": ["19956757", "2775953", "10.1371/journal.pone.0007965"]}, {"Citation": "Anguille, S., Van de Velde, A. L., Smits, E. L., Van Tendeloo, V. F., Juliusson, G., Cools, N., et al. (2017). Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood, 130(15), 1713\u20131721.", "ArticleIdList": ["28830889", "5649080", "10.1182/blood-2017-04-780155"]}, {"Citation": "Hobo, W., Novobrantseva, T. I., Fredrix, H., Wong, J., Milstein, S., Epstein-Barash, H., et al. (2013). Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunology, Immunotherapy, 62(2), 285\u2013297.", "ArticleIdList": ["22903385", "10.1007/s00262-012-1334-1"]}, {"Citation": "Shin, J. H., Shin, D. H., & Kim, J. S. (2020). Let-7 miRNA and CDK4 siRNA co-encapsulated in Herceptin-conjugated liposome for breast cancer stem cells. Asian Journal of Pharmaceutical Sciences, 15(4), 472\u2013481.", "ArticleIdList": ["32952670", "10.1016/j.ajps.2019.03.001"]}, {"Citation": "Xu, C., Li, D., Cao, Z., Xiong, M., Yang, X., & Wang, J. (2019). Facile hydrophobization of siRNA with anticancer drug for non-cationic nanocarrier-mediated systemic delivery. Nano Letters, 19(4), 2688\u20132693.", "ArticleIdList": ["30844291", "10.1021/acs.nanolett.9b00657"]}, {"Citation": "Amreddy, N., Babu, A., Panneerselvam, J., Srivastava, A., Muralidharan, R., Chen, A., et al. (2018). Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomedicine, 14(2), 373\u2013384.", "ArticleIdList": ["29155362", "10.1016/j.nano.2017.11.010"]}, {"Citation": "Taratula, O., Kuzmov, A., Shah, M., Garbuzenko, O. B., & Minko, T. (2013). Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. Journal of Controlled Release, 171(3), 349\u2013357.", "ArticleIdList": ["23648833", "3766401", "10.1016/j.jconrel.2013.04.018"]}, {"Citation": "Li, X., An, Sun, Liu, Y.-j, Zhang, W.-J., Pang, N., Cheng, S.-X., et al. (2018). Amphiphilic dendrimer engineered nanocarrier systems for co-delivery of siRNA and paclitaxel to matrix metalloproteinase-rich tumors for synergistic therapy. NPG Asia Materials, 10(4), 238\u201354.", "ArticleIdList": ["10.1038/s41427-018-0027-4"]}, {"Citation": "Jose, A., Labala, S., & Venuganti, V. V. (2017). Co-delivery of curcumin and STAT3 siRNA using deformable cationic liposomes to treat skin cancer. Journal of Drug Targeting, 25(4), 330\u2013341.", "ArticleIdList": ["27819148", "10.1080/1061186X.2016.1258567"]}, {"Citation": "Luo, K., Gao, Y., Yin, S., Yao, Y., Yu, H., Wang, G., et al. (2021). Co-delivery of paclitaxel and STAT3 siRNA by a multifunctional nanocomplex for targeted treatment of metastatic breast cancer. Acta Biomaterialia, 134, 649\u2013663.", "ArticleIdList": ["34289420", "10.1016/j.actbio.2021.07.029"]}, {"Citation": "Joshi, N., Hajizadeh, F., Ansari Dezfouli, E., Zekiy, A. O., Nabi Afjadi, M., Mousavi, S. M., et al. (2021). Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression. Life Sciences, 275, 119369.", "ArticleIdList": ["33745894", "10.1016/j.lfs.2021.119369"]}, {"Citation": "Wang, L., & Liang, T. T. (2020). CD59 receptor targeted delivery of miRNA-1284 and cisplatin-loaded liposomes for effective therapeutic efficacy against cervical cancer cells. AMB Express, 10(1), 54.", "ArticleIdList": ["32185543", "7078418", "10.1186/s13568-020-00990-z"]}, {"Citation": "Yang, H., Liu, Y., Qiu, Y., Ding, M., & Zhang, Y. (2019). MiRNA-204-5p and oxaliplatin-loaded silica nanoparticles for enhanced tumor suppression effect in CD44-overexpressed colon adenocarcinoma. International Journal of Pharmaceutics, 566, 585\u2013593.", "ArticleIdList": ["31181310", "10.1016/j.ijpharm.2019.06.020"]}, {"Citation": "Liu, A., Zhou, Y., Zhao, T., Tang, X., Zhou, B., & Xu, J. (2021). MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism. Cancer Chemotherapy and Pharmacology, 88(2), 343\u2013357.", "ArticleIdList": ["33993382", "10.1007/s00280-021-04289-z"]}, {"Citation": "Ngamcherdtrakul, W., Reda, M., Nelson, M. A., Wang, R., Zaidan, H. Y., Bejan, D. S., et al. (2021). In situ tumor vaccination with nanoparticle co-delivering CpG and STAT3 siRNA to effectively induce whole-body antitumor immune response. Advanced Materials, 33(31), e2100628.", "ArticleIdList": ["34118167", "10.1002/adma.202100628"]}, {"Citation": "Cafri, G., Gartner, J. J., Zaks, T., Hopson, K., Levin, N., Paria, B. C., et al. (2020). mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. The Journal of Clinical Investigation, 130(11), 5976\u20135988.", "ArticleIdList": ["33016924", "7598064", "10.1172/JCI134915"]}, {"Citation": "Sebastian, M., Papachristofilou, A., Weiss, C., Fr\u00fch, M., Cathomas, R., Hilbe, W., et al. (2014). Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive\u00ae) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer, 14, 748.", "ArticleIdList": ["25288198", "4195907", "10.1186/1471-2407-14-748"]}, {"Citation": "Weide, B., Pascolo, S., Scheel, B., Derhovanessian, E., Pflugfelder, A., Eigentler, T. K., et al. (2009). Direct injection of protamine-protected mRNA: Results of a phase 1/2 vaccination trial in metastatic melanoma patients. Journal of Immunotherapy, 32(5), 498\u2013507.", "ArticleIdList": ["19609242", "10.1097/CJI.0b013e3181a00068"]}, {"Citation": "El Dika, I., Lim, H. Y., Yong, W. P., Lin, C.-C., Yoon, J.-H., Modiano, M., et al. (2019). An open-label, multicenter, phase i, dose escalation study with phase ii expansion cohort to determine the safety, pharmacokinetics, and preliminary antitumor activity of intravenous TKM-080301 in subjects with advanced hepatocellular carcinoma. The Oncologist, 24(6), 747-e218.", "ArticleIdList": ["30598500", "10.1634/theoncologist.2018-0838"]}, {"Citation": "Golan, T., Khvalevsky, E. Z., Hubert, A., Gabai, R. M., Hen, N., Segal, A., et al. (2015). RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget, 6(27), 24560\u201324570.", "ArticleIdList": ["26009994", "4695206", "10.18632/oncotarget.4183"]}, {"Citation": "Kumthekar, P., Ko, C. H., Paunesku, T., Dixit, K., Sonabend, A. M., Bloch, O., et al. (2021). A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. Science Translational Medicine, 13(584)"}, {"Citation": "Hong, D. S., Kang, Y.-K., Borad, M., Sachdev, J., Ejadi, S., Lim, H. Y., et al. (2020). Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. British Journal of Cancer, 122(11), 1630\u20131637.", "ArticleIdList": ["32238921", "7251107", "10.1038/s41416-020-0802-1"]}, {"Citation": "van Zandwijk, N., Pavlakis, N., Kao, S. C., Linton, A., Boyer, M. J., Clarke, S., et al. (2017). Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study. The lancet Oncology, 18(10), 1386\u20131396.", "ArticleIdList": ["28870611", "10.1016/S1470-2045(17)30621-6"]}, {"Citation": "Tanaka, H., Hazama, S., Iida, M., Tsunedomi, R., Takenouchi, H., Nakajima, M., et al. (2017). miR-125b-1 and miR-378a are predictive biomarkers for the efficacy of vaccine treatment against colorectal cancer. Cancer Science, 108(11), 2229\u20132238.", "ArticleIdList": ["28859241", "5666028", "10.1111/cas.13390"]}, {"Citation": "An efficacy study of adjuvant treatment with the personalized cancer vaccine mRNA-4157 and pembrolizumab in participants with high-risk melanoma (KEYNOTE-942). ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/record/NCT03897881 . Accessed 1 Jul 2023."}, {"Citation": "Bauman, J., Burris, H., Clarke, J., Patel, M., Cho, D., Gutierrez, M., et al. (2020). 798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): An update. Journal for ImmunoTherapy of Cancer, 8(Suppl 3), A477."}, {"Citation": "Zhan, X., Wang, B., Wang, Y., Chen, L., Peng, X., Li, J., et al. (2020). Phase I trial of personalized mRNA vaccine encoding neoantigen in patients with advanced digestive system neoplasms. Journal of Clinical Oncology, 38(15_suppl), e15269-e.", "ArticleIdList": ["10.1200/JCO.2020.38.15_suppl.e15269"]}, {"Citation": "A study of mRNA-5671/V941 as monotherapy and in combination with pembrolizumab (V941-001): ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/study/NCT03948763 . Accessed 1 Jul 2023."}, {"Citation": "Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021). From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases. Molecular Aspects of Medicine, 81, 101003.", "ArticleIdList": ["34332771", "10.1016/j.mam.2021.101003"]}, {"Citation": "Zhu, Y., Zhu, L., Wang, X., & Jin, H. (2022). RNA-based therapeutics: An overview and prospectus. Cell Death & Disease, 13(7), 644.", "ArticleIdList": ["10.1038/s41419-022-05075-2"]}, {"Citation": "Shahbazi, R., Ozpolat, B., & Ulubayram, K. (2016). Oligonucleotide-based theranostic nanoparticles in cancer therapy. Nanomedicine (London, England), 11(10), 1287\u20131308.", "ArticleIdList": ["27102380", "10.2217/nnm-2016-0035"]}], "ReferenceList": [], "Title": "References"}], "History": [{"Year": "2023", "Month": "6", "Day": "19"}, {"Year": "2024", "Month": "2", "Day": "20", "Hour": "11", "Minute": "50"}, {"Year": "2023", "Month": "7", "Day": "4", "Hour": "13", "Minute": "8"}, {"Year": "2023", "Month": "7", "Day": "4", "Hour": "11", "Minute": "8"}], "PublicationStatus": "ppublish", "ArticleIdList": ["37402038", "10.1007/s12010-023-04597-5", "10.1007/s12010-023-04597-5"]}}], "PubmedBookArticle": []}